Guyasuta Investment Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.73M Sell
113,231
-7,286
-6% -$191K 0.14% 83
2026
Q1
$3.38M Sell
120,517
-7,494
-6% -$200K 0.2% 69
2025
Q4
$3.19M Sell
128,011
-1,875
-1% -$47.3K 0.18% 68
2025
Q3
$3.31M Sell
129,886
-649
-0.5% -$16K 0.19% 66
2025
Q2
$3.16M Sell
130,535
-2,115
-2% -$49.3K 0.19% 67
2025
Q1
$3.36M Sell
132,650
-567
-0.4% -$14.8K 0.22% 61
2024
Q4
$3.53M Sell
133,217
-11,829
-8% -$321K 0.22% 58
2024
Q3
$4.2M Sell
145,046
-122,116
-46% -$3.56M 0.26% 55
2024
Q2
$7.69M Sell
267,162
-3,093
-1% -$85.2K 0.57% 39
2024
Q1
$7.78M Sell
270,255
-1,786
-0.7% -$49.6K 0.56% 39
2023
Q4
$7.83M Sell
272,041
-622,742
-70% -$18.8M 0.57% 39
2023
Q3
$29.7M Sell
894,783
-2,144
-0.2% -$75.8K 2.3% 15
2023
Q2
$32.9M Sell
896,927
-9,883
-1% -$385K 2.43% 13
2023
Q1
$37M Buy
906,810
+8,316
+0.9% +$359K 2.86% 11
2022
Q4
$46M Buy
898,494
+14,332
+2% +$687K 3.63% 7
2022
Q3
$38.7M Buy
884,162
+2,818
+0.3% +$137K 3.34% 8
2022
Q2
$46.2M Sell
881,344
-792
-0.1% -$40.4K 3.61% 6
2022
Q1
$45.7M Sell
882,136
-5,311
-0.6% -$276K 3.14% 8
2021
Q4
$52.4M Sell
887,447
-9,954
-1% -$493K 3.43% 6
2021
Q3
$38.6M Buy
897,401
+189
+0% +$8.37K 2.75% 11
2021
Q2
$35.1M Buy
897,212
+21,219
+2% +$825K 2.53% 13
2021
Q1
$31.7M Buy
875,993
+30,483
+4% +$1.08M 2.48% 13
2020
Q4
$31.1M Sell
845,510
-39,247
-4% -$1.44M 2.6% 14
2020
Q3
$30.8M Sell
884,757
-685
-0.1% -$24K 2.86% 10
2020
Q2
$27.5M Sell
885,442
-2,569
-0.3% -$87.3K 2.82% 11
2020
Q1
$27.5M Sell
888,011
-7,433
-0.8% -$253K 3.3% 9
2019
Q4
$33.3M Buy
895,444
+25,309
+3% +$901K 3.23% 8
2019
Q3
$29.7M Buy
870,135
+29,342
+3% +$1.07M 3.07% 9
2019
Q2
$34.6M Buy
840,793
+23,136
+3% +$919K 3.59% 6
2019
Q1
$32.9M Sell
817,657
-8,195
-1% -$328K 3.67% 4
2018
Q4
$34.2M Buy
825,852
+2,539
+0.3% +$105K 4.22% 3
2018
Q3
$34.4M Sell
823,313
-17,649
-2% -$679K 3.67% 4
2018
Q2
$28.9M Buy
840,962
+480
+0.1% +$16.4K 3.32% 4
2018
Q1
$28.3M Buy
840,482
+24,987
+3% +$859K 3.31% 5
2017
Q4
$28M Sell
815,495
-3,272
-0.4% -$112K 3.18% 6
2017
Q3
$27.7M Sell
818,767
-6,952
-0.8% -$223K 3.35% 6
2017
Q2
$26.3M Buy
825,719
+4,398
+0.5% +$139K 3.16% 6
2017
Q1
$26.7M Sell
821,321
-5,016
-0.6% -$158K 3.22% 6
2016
Q4
$25.5M Buy
826,337
+71,779
+10% +$2.19M 3.29% 6
2016
Q3
$24.2M Buy
754,558
+12,202
+2% +$408K 3.09% 7
2016
Q2
$24.8M Buy
742,356
+1,263
+0.2% +$40.3K 3.32% 4
2016
Q1
$20.8M Buy
741,093
+10,356
+1% +$296K 2.9% 9
2015
Q4
$22.4M Sell
730,737
-7,188
-1% -$226K 3.15% 9
2015
Q3
$22M Sell
737,925
-27,653
-4% -$887K 3.2% 3
2015
Q2
$24.4M Buy
765,578
+10,287
+1% +$335K 3.23% 3
2015
Q1
$24.9M Buy
755,291
+6,214
+0.8% +$198K 3.35% 3
2014
Q4
$22.1M Sell
749,077
-8,959
-1% -$257K 2.98% 7
2014
Q3
$21.3M Sell
758,036
-10,161
-1% -$285K 2.96% 5
2014
Q2
$21.6M Buy
768,197
+24,285
+3% +$692K 2.86% 7
2014
Q1
$22.7M Buy
743,912
+27,174
+4% +$810K 3.23% 3
2013
Q4
$20.8M Buy
716,738
+3,625
+0.5% +$106K 3.04% 5
2013
Q3
$19.4M Buy
713,113
+10,924
+2% +$297K 3.1% 6
2013
Q2
$18.7M Buy
+702,189
New +$19.4M 3.05% 5

Other funds holding PFE

Guyasuta Investment Advisors's PFE Position: Q2 2026 in Review

Guyasuta Investment Advisors reduced its Pfizer (PFE) stake by 6% in Q2 2026, selling an estimated $191K and leaving 113,231 shares worth $2.73M. The position accounts for 0.14% of the portfolio, ranked #83.

Guyasuta Investment Advisors first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $52.4M in Q4 2021. 1,264 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Guyasuta Investment Advisors held 113,231 shares of Pfizer worth $2.73M as of Q2 2026.
  • Guyasuta Investment Advisors sold 7,286 Pfizer shares in Q2 2026, an estimated $191K.
  • Pfizer made up 0.14% of Guyasuta Investment Advisors's portfolio in Q2 2026, its #83 holding.
  • Guyasuta Investment Advisors first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Guyasuta Investment Advisors's Pfizer position peaked at $52.4M in Q4 2021.
  • 1,264 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Guyasuta Investment Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.